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CASE REPORT
Acute exacerbation of interstitial 
pneumonia associated with rheumatoid arthritis 
during the course of treatment for Pneumocystis 
jirovecii pneumonia: a case report
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Abstract 
Background: Pneumocystis jirovecii pneumonia (PCP) is potentially fatal infectious complication in patients with 
rheumatoid arthritis (RA) during immunosuppressive therapy. Hospital survival due to human immunodeficiency 
virus—unrelated PCP reaches to 60 %. The high mortality rate results from difficulties in establishing an early diagno-
sis, concurrent use of prophylactic drugs, possible bacterial coinfection. We herein report a case of PCP in RA patients 
who developed the architectural distortions of lung in spite of combined modality therapy.
Case presentation: A 73-year-old Japanese woman with RA was admitted with shortness of breath. Five weeks 
previously, she had been started on etanercept in addition to methotrexate (MTX). Chest computed tomography (CT) 
demonstrated diffuse ground glass opacities distributed throughout the bilateral middle to lower lung fields, and 
serum β-d-glucan was elevated. Bronchoalveolar lavage fluid revealed no P. jirovecii, but the organism was detected 
by polymerase chain reaction method. Trimethoprim/sulfamethoxazole was administered with methylprednisolone 
pulse therapy. However, the follow-up chest X-ray and chest CT demonstrated aggravation of the pneumonia with 
architectural distortions. Additional direct hemoperfusion with polymyxin B-immobilized fibers and intravenous 
cyclophosphamide therapy were insufficiently effective, and the patient died on day 25.
Conclusion: The architectural distortions of lung should be considered as a cause of death of PCP. For this reason, a 
high suspicion of this infectious complication must be kept in mind in order to establish an early diagnosis and treat-
ment in patients with RA managed with MTX and biologics.
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Background
Pneumonia is among the most frequent potentially fatal 
infectious complication in patients who are immuno-
compromised. The incidence of Pneumocystis jirovecii 
pneumonia (PCP) is estimated to be 0.2–0.5 % in patients 
with rheumatoid arthritis (RA) undergoing therapy with 
biologics in Japan [1]. The most frequent symptoms are 
progressive dyspnea, dry cough and a low-grade fever 
[2]. Interstitial lung disease (ILD) is a well-established 
and debilitating extra-articular manifestation of RA. ILD 
is the primary form of pulmonary involvement in RA, 
with a prevalence ranging from 4 to 68 %, mostly in the 
50–60-year age group [3]. Respiratory symptoms may 
precede the onset of articular symptoms in 10–20  % of 
cases [4]. Pulmonary fibrosis including multiple thin-
walled cysts, which varies in occurrence and severity, is 
radiographically evident in 10–34  % with PCP patients 
[5]. In patients with acquired immune deficiency syn-
drome (AIDS), morphological changes at the late stage 
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of infection have been frequently reported. However, 
there have been few reports on such late morphological 
changes in non- human immunodeficiency virus (HIV) 
patients [1, 6–9]. The most common pattern in the early 
phase of the lung disease is wide distribution of ground 
glass opacities (GGOs) with a preference for the api-
cal and central lung regions [1, 3, 6, 10–12]. There are 
few data about the course, duration and morphologi-
cal changes in patients with PCP who are not immuno-
compromised due to HIV. Here we report a case of PCP 
associated with the use of etanercept in a patient with RA 
who developed architectural distortions.
Case report
A 73-year-old Japanese woman had been diagnosed as 
having RA 5  years before presentation and was initially 
treated with etanercept at 50  mg/week. Her family his-
tory included no consanguinity or collagen diseases. 
Two years before presentation, she had suffered tuber-
culous cervical lymphadenitis and had stopped taking 
etanercept because of remission. After 1  year, she was 
diagnosed as having interstitial pneumonia by chest com-
puted tomography (CT) (Fig. 1a). Her RA disease activity 
gradually increased, and she was started on methotrexate 
(MTX) at 6 mg/week 18 months before presentation. She 
was referred to our hospital because of her increasing 
disease activity. Because control of the RA was incom-
plete, the dose of MTX was gradually increased to 10 mg/
week. Two month before treatment of biologics, chest 
X-ray was performed and diagnosed as having intersti-
tial pneumonia again (Fig. 1b). As the disease was refrac-
tory, biological therapy with etanercept at 25  mg/week 
was readministered when the RA was diagnosed as class 
2, stage II. Five weeks later, she presented at our hospi-
tal complaining of cough and shortness of breath that 
had persisted for 2  weeks. On admission, the patient’s 
body temperature was 35.7  °C and her respiratory rate 
was 18  breaths/min. Chest auscultation revealed bilat-
eral fine crackles. Arterial blood gas analysis on 2L of O2 
via a nasal cannula showed a pH of 7.41, PaO2 89.3 Torr, 
PaCO2 38.1  Torr, and HCO3− 23.7  mmol/L. Laboratory 
examinations revealed a white blood cell count of 6930/
μL (neutrophils: 97.0 %, lymphocytes: 3.0 %, monocytes: 
0.0 %, eosinophils: 0.0 %, basophils: 0.0 %), lactate dehy-
drogenase 424 IU/L, C-reactive protein 20.7 mg/dL, pro-
calcitonin 0.83  ng/mL, sialylated carbohydrate antigen 
Krebs von den Lungen-6 (KL-6) 1035  U/mL, surfactant 
protein D (SP-D) 262.9  ng/mL, and β-d-glucan 158  U/
mL. Although the CT findings did not suggest malig-
nancy, the levels of tumor markers such as carcinoembry-
onic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), 
and soluble interleukin-2 receptor (sIL-2R) were elevated 
at 8.5 ng/mL, 799 and 2954 U/mL, respectively. In addi-
tion, an HIV test had a negative result. A chest X-ray 
showed demonstrated GGOs in the middle and lower 
lung fields. High-resolution CT (HRCT) showed GGOs 
with thickened interlobular septa and traction bronchiec-
tasis (Fig. 2). We suspected that the patient had PCP, but 
MTX-induced lung disease and cytomegalovirus pneu-
monia were included in the differential diagnosis. We 
then stopped the MTX therapy and started the patient 
on trimethoprim/sulfamethoxazole (SMX/TMP) at a 
TMP dose of 720  mg daily with empirical meropenem 
antibiotic therapy. On the 2nd hospital day, chest CT was 
Fig. 1 Chest CT and chest X-ray before treatment with biologics. a Chest CT was performed 10 month before admission. Mild reticular shadow was 
observed in the bilateral lower lung. b Chest X-ray was performed 2 month before admission. Mild reticular shadow was observed in the bilateral 
lower lung again
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performed again and this showed that CT-attenuation 
of pulmonary infiltrates had increased and the begin-
ning of architectural distortions was evident (Fig.  3a). 
Bronchoscopy was performed on the third hospital day. 
Bronchoalveolar lavage (BAL) performed in the right 
middle lobe yielded 20  mL of fluid, but no significant 
pathogens were cultured from it. However, the results 
of polymerase chain reaction (PCR) for P. jirovecii were 
positive, even though para-aminosalicylic acid and Gro-
cott-Gomori methenamine silver nitrate staining of the 
BAL fluid revealed no P. jirovecii cysts. The patient was 
diagnosed as having PCP, and SMX/TMP was adminis-
tered for 14 days. On the 14th hospital day, skin eruption 
was observed, and this was considered to be a drug reac-
tion; therefore SMX/TMP was switched to pentamidine. 
On the 14th hospital day, the patient developed dyspnea 
and her coughing increased. In addition, the PaO2 on 3L 
of O2 per cannula decreased to 63.4 Torr. A chest X-ray 
and HRCT performed on the 8th hospital day showed an 
increase in GGO and parenchymal consolidations with 
progression of the architectural distortions and pleu-
ral effusion (Fig.  3b, c). These findings were considered 
to reflect an immune response due to the treatment for 
PCP with SMX/TMP alone. Therefore, we administered 
methylprednisolone from 2nd hospital day (500  mg/day 
intravenously for 3  days, followed by 250  mg/day intra-
venously for 3  days and 125  mg/day intravenously for 
3 days). Shortness of breath was progressive and satura-
tion of O2 was decreased, necessitating readministra-
tion of methylprednisolone from the 11th hospital day 
(1000 mg/day intravenously for 3 days and then 500 mg/
day intravenously for 3 days). In addition, direct hemop-
erfusion using a polymyxin B-immobilized fiber column 
was performed on the 11th hospital day. A chest X-ray 
performed on the 15th hospital day showed an increase 
in GGO with pleural effusion (Fig. 3d). The patient’s res-
piratory condition worsened, and 500 mg of intravenous 
cyclophosphamide was added on the 18th hospital day. 
Repeated examination of chest X-ray was performed 
on the 18th and 21st day and revealed no improvement 
(Fig.  3e, f ). However, The β-d-glucan level was not ele-
vated at any time during the patient’s hospital course. It is 
known that the level of KL-6, a marker of interstitial lung 
disease, is increased in patients with PCP. The KL-6 level 
in our patient was 1441 U/mL on the 10th hospital day 
and 1585  U/mL on the 11th hospital day. However, the 
patient’s respiratory status deteriorated rapidly, and she 
died on the 25th day of hospitalization (Fig. 4).
Discussion
The incidence of P. jirovecii pneumonia (PCP) is estimated 
to be 0.2–0.5 % in patients with rheumatoid arthritis (RA) 
undergoing therapy with biologics in Japan [1]. It was indi-
cated that combination therapies with MTX and biologics 
for RA are a common risk factor for PCP [13]. Advanced 
age or existing RA lung involvement are also reportedly 
associated with PCP [11]. Our RA patient who was treated 
with MTX and etenercept was over 60 years of age and had 
pre-existing mild interstitial pneumonia and bronchiecta-
sis. Additionally, she was treated with etanercept as well 
as MTX, but developed PCP only 1 month after the start 
of etanercept administration. It is possible that the rapid 
change of immune status after treatment with etanercept 
and MTX might have led to PCP.
Tasaka et  al. [12] have suggested that a diagnosis of 
PCP should be made based on a β-d-glucan level and 
positive findings for P. jirovecii in BAL fluid on PCR. It 
has been reported that in non-HIV-infected patients, 
such as those with RA with PCP, the number of organ-
isms in the airways is relatively (10- to 100-fold) low in 
comparison with patients who have AIDS-related condi-
tions [11, 12, 14, 15]. In the present case, the diagnosis of 
PCP was based on elevation the of β-d-glucan level and 
PCR positivity for P. jirovecii in BAL fluid. However, no 
significant pathogens were cultured from the BAL fluid, 
and P. jirovecii was not detected by Grocott-Gomori 
methenamine silver nitrate staining.
Fig. 2 Chest high-resolution CT at the time of admission. A chest 
high-resolution CT (HRCT) showed GGOs in the lower lung field with 
thickened interlobular septa and traction bronchiectasis
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Fig. 3 Chest CT and chest X-ray in the clinical course of the patient. a Chest CT showed that CT-attenuation of pulmonary infiltrates had increased 
and the beginning of architectural distortions was evident (second hospital day). b, c A chest X-ray and CT showed an increase in GGO and paren-
chymal consolidations with progression of the architectural distortions and pleural effusion (8th hospital day). d A chest X-ray showed an increase 
in GGO with pleural effusion (15th hospital day). e A chest X-ray showed no change in GGO with pleural effusion in spite of direct hemoperfusion 
using a polymyxin B-immobilized fiber column (18th hospital day). f A chest X-ray showed an increase in GGO with pleural effusion in spite of intra-
venous cyclophosphamide therapy (21st hospital day)
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Upon imaging, the initial appearance of PCP on chest 
CT was symmetrical, apically distributed GGOs with a 
perihilar location, a mosaic and consolidations pattern 
[1, 3, 6, 10–12]. In such cases, the density of infiltrates 
slowly increases and a mosaic pattern with architectural 
distortions can evolve from GGOs if appropriate treat-
ment is not provided. Furthermore it has been shown 
that GGOs rapidly improve after the treatment of specific 
therapy. Tokuda et al. [16] reported that RA-related PCP 
shows both diffuse homogeneous GGOs and homoge-
neous or non-homogeneous GGO with sharp demarca-
tion in the intralobular septa on chest CT. Chest CT in 
the present case revealed homogeneous GGOs demar-
cated from the non-affected lung by interlobular septa. 
Additionally, architectural distortions with irregular lin-
ear opacities, reticulations and traction bronchiolectasis 
were observed, and showed irreversible progression. The 
reason for these architectural distortions in unclear. With 
regard to fibrosis, Pareja et  al. [17] have suggested sev-
eral effects of modulation of the host immune response 
by P. jirovecii itself, such as pulmonary immune clearance 
and other mechanisms. Additionally, it has been not 
completely clarified that the relationship between anti-
inflammatory effects and the gas exchange abnormality, 
modulation of the host immune response, enhanced of 
effector function to P. jirovecii, enhancement of immune 
clearance mechanisms of lung. In more than one-third of 
HIV-negative PCP patients, it has recently been demon-
strated that irregular linear opacities, reticulations and 
traction bronchiectasis were present as architectural 
distortions. During follow-up for PCP, these signs were 
reversible completely in more than two-third of them. 
However, postinfectious fibrosis rarely occurs following 
PCP. On the other hand, later expansion of lethal inter-
stitial pneumonia despite low levels of serum β-d-glucan 
may characterize PCP in RA patients who have pre-exist-
ing pulmonary lesions. A previous pathological study of 
HIV-positive PCP patients revealed that the occurrence 
of fibrosis was variable in autopsy specimens. Either 
fibroblastic organization of intraalveolar exudates (fibros-
ing alveolitis) or PCP per se had been reported as causes 
or promoters of fibrosis [7]. Pentamidine has frequently 
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Fig. 4 Clinical course of the patient with Pneumocystis jirovecii pneumonia. Interstitial pneumonia with architectural distortions was progressed in 
spite of the treatment with methylprednisolone pulse therapy, direct hemoperfusion with polymyxin B-immobilized fibers and intravenous cyclo-
phosphamide therapy
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been used for treatment of PCP, as in the present case, but 
recently atovaquone has been used for both prophylaxis 
and treatment. The effects of pulmonary fibrosis after 
treatment of PCP have not been reported, and further 
investigations of atovaquone treatment are necessary. It 
is assumed that the use of adjunctive steroid therapy to 
reduce the respiratory complications with PCP is ben-
eficial in non-HIV patients [17]. This, with initiation of 
early diagnosis and the treatment, might explain the 
rare occurrence of fibrosis and the reversibility of archi-
tectural distortions. In the present case, repeated pulse 
methylprednisolone therapy was performed together 
with specific antibiotic therapy during the course of dis-
ease, but the effects were insufficient. Therefore, direct 
hemoperfusion using a polymyxin B-immobilized fiber 
column and intravenous cyclophosphamide therapy were 
added, because these treatments have sometimes been 
performed in cases of acute interstitial pneumonia [18]. 
However, these treatments were not sufficient to arrest 
the progression of interstitial pneumonia.
Prophylactic treatment for PCP with TMP/SMX 
should be considered for high-risk patients. However, a 
recent review considered that it was impossible to pre-
dict which patients would benefit the most from TMP/
SMZ, and that thousands of subjects would need to be 
studied before the benefit of TMP/SMZ was proven [19]. 
TMP/SMZ for prophylaxis might be considered in high-
risk patients such as those with interstitial pneumonia 
and bronchiectasis.
Conclusions
The PCP is a potentially fatal condition in immunocom-
promised hosts. The architectural distortions of lung 
should be considered as a cause of death of PCP. For 
this reason, a high suspicion of this infectious complica-
tion must be kept in mind in order to establish an early 
diagnosis and treatment in patients with RA managed 
with MTX and biologics. Further accumulation of similar 
cases is needed to clarify the etiology and treatment of 
the architectural distortions.
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